Feb 11 (Reuters) - AstraZeneca on Thursday forecast 2021 revenue growth after the COVID-19 vaccine developer beat analyst’s estimates for fourth-quarter product sales, as a wide range of therapies helped cushion the hit from the pandemic. (Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; Editing by Shounak Dasgupta)
我们的标准: 汤森路透“信任原则”